Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 3
2019 1
2020 4
2021 2
2022 3
2023 1
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Targeting alternative splicing as a new cancer immunotherapy-phosphorylation of serine arginine-rich splicing factor (SRSF1) by SR protein kinase 1 (SRPK1) regulates alternative splicing of PD1 to generate a soluble antagonistic isoform that prevents T cell exhaustion.
Wahid M, Pratoomthai B, Egbuniwe IU, Evans HR, Babaei-Jadidi R, Amartey JO, Erdelyi V, Yacqub-Usman K, Jackson AM, Morris JC, Patel PM, Bates DO. Wahid M, et al. Cancer Immunol Immunother. 2023 Dec;72(12):4001-4014. doi: 10.1007/s00262-023-03534-z. Epub 2023 Nov 16. Cancer Immunol Immunother. 2023. PMID: 37973660 Free PMC article.
Pharmacology of Modulators of Alternative Splicing.
Bates DO, Morris JC, Oltean S, Donaldson LF. Bates DO, et al. Pharmacol Rev. 2017 Jan;69(1):63-79. doi: 10.1124/pr.115.011239. Pharmacol Rev. 2017. PMID: 28034912 Free PMC article. Review.
Therapeutic Implications of Ceritinib in Cholangiocarcinoma beyond ALK Expression and Mutation.
Myint KZ, Balasubramanian B, Venkatraman S, Phimsen S, Sripramote S, Jantra J, Choeiphuk C, Mingphruedhi S, Muangkaew P, Rungsakulkij N, Tangtawee P, Suragul W, Farquharson WV, Wongprasert K, Chutipongtanate S, Sanvarinda P, Ponpuak M, Poungvarin N, Janvilisri T, Suthiphongchai T, Yacqub-Usman K, Grabowska AM, Bates DO, Tohtong R. Myint KZ, et al. Pharmaceuticals (Basel). 2024 Feb 2;17(2):197. doi: 10.3390/ph17020197. Pharmaceuticals (Basel). 2024. PMID: 38399413 Free PMC article.
Phosphodiesterase type 5 inhibitors enhance chemotherapy in preclinical models of esophageal adenocarcinoma by targeting cancer-associated fibroblasts.
Sharpe BP, Hayden A, Manousopoulou A, Cowie A, Walker RC, Harrington J, Izadi F, Breininger SP, Gibson J, Pickering O, Jaynes E, Kyle E, Saunders JH, Parsons SL, Ritchie AA, Clarke PA, Collier P, Mongan NP, Bates DO, Yacqub-Usman K, Garbis SD, Walters Z, Rose-Zerilli M, Grabowska AM, Underwood TJ. Sharpe BP, et al. Cell Rep Med. 2022 Jun 21;3(6):100541. doi: 10.1016/j.xcrm.2022.100541. Cell Rep Med. 2022. PMID: 35732148 Free PMC article.
14 results